125 related articles for article (PubMed ID: 10614662)
21. The decreased influence of overall treatment time on the response of human breast tumor xenografts following prolongation of the potential doubling time (Tpot).
Sarkaria JN; Fowler JF; Lindstrom MJ; Jordan VC; Mulcahy RT
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):833-40. PubMed ID: 7860396
[TBL] [Abstract][Full Text] [Related]
22. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
23. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
Osborne CK; Hobbs K; Clark GM
Cancer Res; 1985 Feb; 45(2):584-90. PubMed ID: 3967234
[TBL] [Abstract][Full Text] [Related]
24. Estrogens do not modify MAP kinase-dependent nuclear signaling during stimulation of early G(1) progression in human breast cancer cells.
Caristi S; Galera JL; Matarese F; Imai M; Caporali S; Cancemi M; Altucci L; Cicatiello L; Teti D; Bresciani F; Weisz A
Cancer Res; 2001 Sep; 61(17):6360-6. PubMed ID: 11522626
[TBL] [Abstract][Full Text] [Related]
25. Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice.
Dauvois S; Geng CS; Lévesque C; Mérand Y; Labrie F
Cancer Res; 1991 Jun; 51(12):3131-5. PubMed ID: 2039992
[TBL] [Abstract][Full Text] [Related]
26. Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo.
Atlas E; Cardillo M; Mehmi I; Zahedkargaran H; Tang C; Lupu R
Mol Cancer Res; 2003 Jan; 1(3):165-75. PubMed ID: 12556556
[TBL] [Abstract][Full Text] [Related]
27. Long-term exposure to tamoxifen induces hypersensitivity to estradiol.
Berstein LM; Wang JP; Zheng H; Yue W; Conaway M; Santen RJ
Clin Cancer Res; 2004 Feb; 10(4):1530-4. PubMed ID: 14977857
[TBL] [Abstract][Full Text] [Related]
28. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
29. Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells.
Santen RJ; Song RX; Masamura S; Yue W; Fan P; Sogon T; Hayashi S; Nakachi K; Eguchi H
Adv Exp Med Biol; 2008; 630():19-34. PubMed ID: 18637482
[TBL] [Abstract][Full Text] [Related]
30. Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors.
Nakamura J; Savinov A; Lu Q; Brodie A
Endocrinology; 1996 Dec; 137(12):5589-96. PubMed ID: 8940388
[TBL] [Abstract][Full Text] [Related]
31. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms.
Manole D; Schildknecht B; Gosnell B; Adams E; Derwahl M
J Clin Endocrinol Metab; 2001 Mar; 86(3):1072-7. PubMed ID: 11238488
[TBL] [Abstract][Full Text] [Related]
32. Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance.
Balaburski GM; Dardes RC; Johnson M; Haddad B; Zhu F; Ross EA; Sengupta S; Klein-Szanto A; Liu H; Lee ES; Kim H; Jordan VC
Int J Oncol; 2010 Aug; 37(2):387-98. PubMed ID: 20596666
[TBL] [Abstract][Full Text] [Related]
33. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
34. Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors.
Read LD; Greene GL; Katzenellenbogen BS
Mol Endocrinol; 1989 Feb; 3(2):295-304. PubMed ID: 2785242
[TBL] [Abstract][Full Text] [Related]
35. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.
Gilad LA; Bresler T; Gnainsky J; Smirnoff P; Schwartz B
J Endocrinol; 2005 Jun; 185(3):577-92. PubMed ID: 15930183
[TBL] [Abstract][Full Text] [Related]
36. Upregulation of AIB1, aromatase and ERα provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival.
Tilghman SL; Sabnis G; Brodie AM
Horm Mol Biol Clin Investig; 2010 Dec; 3(1):357-66. PubMed ID: 25961207
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of progesterone receptor membrane component 1: possible mechanism for increased breast cancer risk with norethisterone in hormone therapy.
Neubauer H; Ruan X; Schneck H; Seeger H; Cahill MA; Liang Y; Mafuvadze B; Hyder SM; Fehm T; Mueck AO
Menopause; 2013 May; 20(5):504-10. PubMed ID: 23615641
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth.
Liu Y; Ludes-Meyers J; Zhang Y; Munoz-Medellin D; Kim HT; Lu C; Ge G; Schiff R; Hilsenbeck SG; Osborne CK; Brown PH
Oncogene; 2002 Oct; 21(50):7680-9. PubMed ID: 12400010
[TBL] [Abstract][Full Text] [Related]
39. 17 beta-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation.
Bonapace IM; Addeo R; Altucci L; Cicatiello L; Bifulco M; Laezza C; Salzano S; Sica V; Bresciani F; Weisz A
Oncogene; 1996 Feb; 12(4):753-63. PubMed ID: 8632897
[TBL] [Abstract][Full Text] [Related]
40. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
Berstein LM; Yue W; Wang JP; Santen RJ
Breast Cancer Res Treat; 2011 Jul; 128(1):109-17. PubMed ID: 20683653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
